Shuttle Pharmaceuticals Holdings, Inc. Uncategorized Contracts & Agreements

31 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Pre-Funded Common Stock Purchase Warrant Agreement – Shuttle Pharmaceuticals Holdings, Inc.
Warrant Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
NY
2025
Amendment Agreement to Securities Purchase Agreement among Shuttle Pharmaceuticals Holdings, Inc., Alto Opportunity Master Fund, and Guarantors
Modification Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2025
Change Order #1 to Work Order #3 for Phase 2 IPdR Glioblastoma Study – Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc.
Services Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2025
Sponsored Research Agreement between Shuttle Pharmaceuticals Holdings, Inc. and The Regents of the University of California (UCSF)
Collaboration Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
CA
2024
Pre-Funded Common Stock Purchase Warrant Agreement – Shuttle Pharmaceuticals Holdings, Inc.
Warrant Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
NY
2024
Common Stock Purchase Warrant Agreement between Shuttle Pharmaceuticals Holdings, Inc. and Holder
Warrant Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
NY
2024
Shuttle Pharmaceuticals Holdings, Inc. Form of Common Stock Warrant Agreement
Warrant Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2024
Work Order #3 to Master Service Agreement Between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc. for Phase 2 IPdR Glioblastoma Study
Services Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2024
Amendment Agreement to Securities Purchase Agreement among Shuttle Pharmaceuticals Holdings, Inc., Alto Opportunity Master Fund, and Guarantors (August 6, 2024)
Modification Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2024
Amendment No. 1 to Amendment Agreement among Shuttle Pharmaceuticals Holdings, Inc. and Alto Opportunity Master Fund
Modification Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2023
Amendment Agreement to Securities Purchase Agreement and Related Documents between Shuttle Pharmaceuticals Holdings, Inc. and Alto Opportunity Master Fund, SPC – Segregated...
Modification Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2023
Materials Transfer Agreement between Georgetown University and Shuttle Pharmaceuticals, Inc.
Collaboration Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2023
Research Agreement, dated March 16, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2023
Letter Agreement Regarding Proceeds of Senior Secured Convertible Note between Alto Opportunity Master Fund and Shuttle Pharmaceutical Holdings
Note Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2023
Shuttle Pharmaceuticals Holdings, Inc. Amended and Restated Insider Trading Policy (March 2023)
Code of Ethics
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2023
Director Offer Letter Agreement between Shuttle Pharmaceuticals Holdings, Inc. and Milton Brown, MD, PhD
Employment Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
DE
2023
Director Offer Letter Agreement between Shuttle Pharmaceuticals Holdings, Inc. and Bette Jacobs, PhD
Employment Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
DE
2022
Process Development and cGMP Manufacturing Agreement between Shuttle Pharmaceuticals Holdings, Inc. and TCG GreenChem, Inc.
Development Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
First Amendment to Non-Disclosure, Evaluation and Option Agreement, dated November 30, 2019, between Shuttle Pharmaceutical, Inc. and University of Virginia Licensing & Ventures...
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
Non-Disclosure, Evaluation and Option Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals, Inc. and University of Virginia Licensing & Ventures Group
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
Director Offer Letter, dated December 2, 2020, between Chris Senanayake and Shuttle Pharmaceuticals Holdings, Inc
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
SBIR Phase II Contract #75N9101C00031, dated September 6, 2019, between Shuttle Pharmaceuticals, Inc. and National Institute of Health National Cancer Institute
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
SBIR Contract #HHSN261201800016C/75N91018C00016 Agreement between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
Sublicense Agreement, dated February 15, 2019, between Shuttle Pharmaceuticals Inc. and Propagenix, Inc
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
Subaward Agreement dated October 28, 2014 between Shuttle Pharmaceuticals, LLC and LifeSpan/Rhode Island Hospital
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
Director Offer Letter Agreement between Shuttle Pharmaceuticals Holdings, Inc. and Director
Consulting Agreements
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
DE
2022
Material Transfer Agreement, dated April 25, 2017, between Shuttle Pharmaceuticals, Inc. and George Washington University
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
SBIR Contract #HHSN261600038C dated September 19, 2016 between Shuttle Pharmaceuticals, LLC. and National Institute of Health National Cancer Institute
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
SBIR Contract #HHSN261201600027C, dated September 19, 2016, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
SBIR Contract #HHSN261201400013C Amendment of Solicitation/Modification of Contract, dated August 3, 2015, between Shuttle Pharmaceuticals, LLC and National Institute of Health...
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022
SBIR Contract #HHSN261201400013C, dated September 19, 2014, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute
Shuttle Pharmaceuticals Holdings, Inc.
Biotechnology
2022